Cellsource

Cell Source, Inc. develops cell therapy treatments focused on managing immune tolerance. Its patented Veto-Cell technology selectively modifies the immune response, preventing transplant rejection while preserving other immune functions. This innovation offers therapeutic potential across stem cell transplantation, certain cancers, and organ transplants.

Established June 6, 2012, Cell Source emerged from scientific insight into precise immune system modulation. Founders recognized the critical need for therapies inducing immune tolerance without broad immunosuppression, vital for transplant recipients and immune conditions. The Veto-Cell technology evolved from this foundational research, leveraging natural regulatory mechanisms.

The company's technology targets patients needing stem cell or organ transplants, plus individuals battling cancers and non-malignant diseases. Cell Source envisions safer, more effective immunotherapy solutions, enhancing patient outcomes through improved transplant success and novel approaches for immune conditions. Its long-term objective is integrating advanced cell therapies into clinical practice.